Clinical and Applied Thrombosis/Hemostasis · 2017 · 18 citations · 25 references
MedicineOncologyCancer EpidemiologyHematologic OncologyRisk AssessmentPulmonary EmbolismThromboembolic DiseaseThromboembolism PreventionThrombosisThrombosis ManagementVenous ThromboembolismAmbulatory Venous ThromboembolismCancer-associated Pulmonary EmbolismClinical Practice Guidelines ImplementationHealth Risk Assessment ModelsHospital Electronic Health RecordsMedical Records ReviewRisk Assessment ModelsVenous Thromboembolism Assessment
Venous thromboembolism (VTE) is a commonly encountered problem in patients with cancer. In recent years, cancer treatment paradigm has shifted with most therapy offered in ambulatory outpatient settings. Excess of half VTEs in patients with cancer occur in outpatient settings without prior hospitalization, where current practice guidelines do not recommend routine prophylaxis. Risk assessment models (RAMs) for VTE in such patients were recently introduced. This study aims to assess the practical application of one of these models in clinical practice. Medical records and hospital electronic database were searched for patients with cancer having VTE. Known risk factors were collected, and risk assessment was done using the Khorana RAM. Over a 10-year period, 346 patients developed VTE in ambulatory settings. Median age was 57 and 59.0% were females. Lower extremities were involved in 196 (56.6%), while 96 (27.7%) had pulmonary embolism. Most (76.6%) patients had stage IV disease, only 9.0% had stage I or II disease. Only 156 (45.1%) patients were on active chemotherapy, for whom Khorana risk assessment score was calculated. In these patients, high risk was identified in 31 (19.9%) patients, while 81 (51.9%) had intermediate risk and 44 (28.2%) had low risk. No patients were on prophylaxis prior to VTE. Most ambulatory patients with cancer who developed VTE were not on chemotherapy, and many of those who were on active treatment had low Khorana risk scores. This illustrates the need to modify the model or develop a new one that takes into consideration this group of patients.
25
The National Comprehensive Cancer Network
William T. McGivney · Cancer · 1998 · 16.9K citations
Prevention of VTE in Nonsurgical Patients
Susan R. Kahn, Wendy Lim, Andrew Dunn et al. · CHEST Journal · 2012 · 2.7K citations · Full text
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana, Nicole M. Kuderer, Eva Culakova et al. · Blood · 2008 · 2.2K citations · Full text
Medicine, Hematology, Oncology +14
Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis
Jeanet W. Blom · JAMA · 2005 · 2K citations
Medicine, Genetics, Hematology +14